A Novel Calcium-sensing Receptor Antagonist Leads to Dose-Dependent Transient Release of Parathyroid Hormone after Oral Administration to Healthy Volunteers - an Initial Proof-of-Concept for a Potential New Class of Anabolic Osteoporosis Therapeutics